18F-FDG PET/CT Evaluation of Ceritinib Therapy in Metastatic ALK-Positive Non-small Cell Lung Cancer.
Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancers (NSCLC) account for 3% to 7% of all NSCLC and require a standard treatment by crizotinib. However, crizotinib resistance is frequent within the first 12 months of treatment. Ceritinib is a novel tyrosine kinase inhibitor of ALK recently introduced in France for metastatic or locally advanced crizotinib-resistant ALK NSCLC. We report the first use of ceritinib in our institution with a spectacular tumoral response after only 3 months of treatment. This case demonstrates the major role of F-FDG PET/CT for monitoring the effectiveness of this new treatment.
From the *Unité de Médecine Nucléaire, Institut Jean Godinot, Reims; †Laboratoire de Biophysique, UFR de Médecine, Université de Reims-Champagne Ardenne, Reims; ‡Département d'Oncologie Médicale, Institut Jean Godinot, Reims; and §CReSTIC Centre de Recherche en Sciences et Technologies de l'Information et de la Communication, EA 3804, Université de Reims-Champagne Ardenne, Reims, France.
Sebastien
S
Dejust
David
D
Morland
Guillaume
G
Fabre
Alain
A
Prevost
Dimitri
D
Papathanassiou
D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D009362:Neoplasm Metastasis; D000072078:Positron Emission Tomography Computed Tomography; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D019275:Radiopharmaceuticals; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D013450:Sulfones / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D019275:Radiopharmaceuticals; D013450:Sulfones; D019788:Fluorodeoxyglucose F18; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases; C586847:ceritinib